Skip to main content
Top
Published in: Diabetologia 11/2006

01-11-2006 | Article

PARL Leu262Val is not associated with fasting insulin levels in UK populations

Authors: K. A. Fawcett, N. J. Wareham, J. Luan, H. Syddall, C. Cooper, S. O’Rahilly, I. N. M. Day, M. S. Sandhu, I. Barroso

Published in: Diabetologia | Issue 11/2006

Login to get access

Abstract

Aims/hypothesis

PARL, the gene encoding presenilins-associated rhomboid-like protein, maps to chromosome 3q27 within a quantitative trait locus that influences components of the metabolic syndrome. Recently, an amino acid substitution (Leu262Val, rs3732581) in PARL was associated with fasting plasma insulin levels in a US white population (N=1031). This variant was also found to modify the positive association between age and fasting insulin. The aim of this study was to test whether these findings could be replicated in two UK population-based cohorts.

Methods

Participants from the Medical Research Council Ely and Hertfordshire cohort studies were genotyped for this variant using a SNaPshot primer extension assay and Taqman assay respectively. Full phenotypic and genotypic data were available for 3,666 study participants.

Results

Based on a dominant model, we found no association between the Leu262Val polymorphism and fasting insulin levels (p=0.79) or BMI (p=0.98). We did not observe the previously reported interaction between age and genotype on fasting insulin (p=0.14).

Conclusions/interpretation

Despite having greater statistical power, our data do not support the previously reported association between PARL Leu262Val and fasting plasma insulin levels, a measure of insulin resistance. Our findings indicate that this variant is unlikely to be an important contributor to insulin resistance in UK populations.
Literature
1.
go back to reference Pellegrini L, Passer BJ, Canelles M et al (2001) PAMP and PARL, two novel putative metalloproteases interacting with the COOH-terminus of Presenilin-1 and -2. J Alzheimers Dis 3:181–190PubMed Pellegrini L, Passer BJ, Canelles M et al (2001) PAMP and PARL, two novel putative metalloproteases interacting with the COOH-terminus of Presenilin-1 and -2. J Alzheimers Dis 3:181–190PubMed
2.
go back to reference Koonin EV, Makarova KS, Rogozin IB, Davidovic L, Letellier MC, Pellegrini L (2003) The rhomboids: a nearly ubiquitous family of intramembrane serine proteases that probably evolved by multiple ancient horizontal gene transfers. Genome Biol 4:R19PubMedCrossRef Koonin EV, Makarova KS, Rogozin IB, Davidovic L, Letellier MC, Pellegrini L (2003) The rhomboids: a nearly ubiquitous family of intramembrane serine proteases that probably evolved by multiple ancient horizontal gene transfers. Genome Biol 4:R19PubMedCrossRef
3.
go back to reference McQuibban GA, Saurya S, Freeman M (2003) Mitochondrial membrane remodelling regulated by a conserved rhomboid protease. Nature 423:537–541PubMedCrossRef McQuibban GA, Saurya S, Freeman M (2003) Mitochondrial membrane remodelling regulated by a conserved rhomboid protease. Nature 423:537–541PubMedCrossRef
4.
go back to reference Sik A, Passer BJ, Koonin EV, Pellegrini L (2004) Self-regulated cleavage of the mitochondrial intramembrane-cleaving protease PARL yields Pbeta, a nuclear-targeted peptide. J Biol Chem 279:15323–15329PubMedCrossRef Sik A, Passer BJ, Koonin EV, Pellegrini L (2004) Self-regulated cleavage of the mitochondrial intramembrane-cleaving protease PARL yields Pbeta, a nuclear-targeted peptide. J Biol Chem 279:15323–15329PubMedCrossRef
5.
go back to reference Walder K, Kerr-Bayles L, Civitarese A et al (2005) The mitochondrial rhomboid protease PSARL is a new candidate gene for type 2 diabetes. Diabetologia 48:459–468PubMedCrossRef Walder K, Kerr-Bayles L, Civitarese A et al (2005) The mitochondrial rhomboid protease PSARL is a new candidate gene for type 2 diabetes. Diabetologia 48:459–468PubMedCrossRef
6.
go back to reference Kissebah AH, Sonnenberg GE, Myklebust J et al (2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97:14478–14483PubMedCrossRef Kissebah AH, Sonnenberg GE, Myklebust J et al (2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97:14478–14483PubMedCrossRef
7.
go back to reference Wareham NJ, Hennings SJ, Byrne CD, Hales CN, Prentice AM, Day NE (1998) A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome. Br J Nutr 80:235–241PubMed Wareham NJ, Hennings SJ, Byrne CD, Hales CN, Prentice AM, Day NE (1998) A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome. Br J Nutr 80:235–241PubMed
8.
go back to reference Syddall HE, Aihie Sayer A, Dennison EM, Martin HJ, Barker DJ, Cooper C (2005) Cohort profile: the Hertfordshire cohort study. Int J Epidemiol 34:1234–1242PubMedCrossRef Syddall HE, Aihie Sayer A, Dennison EM, Martin HJ, Barker DJ, Cooper C (2005) Cohort profile: the Hertfordshire cohort study. Int J Epidemiol 34:1234–1242PubMedCrossRef
9.
go back to reference Sobey WJ, Beer SF, Carrington CA et al (1989) Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins. Biochem J 260:535–554PubMed Sobey WJ, Beer SF, Carrington CA et al (1989) Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins. Biochem J 260:535–554PubMed
Metadata
Title
PARL Leu262Val is not associated with fasting insulin levels in UK populations
Authors
K. A. Fawcett
N. J. Wareham
J. Luan
H. Syddall
C. Cooper
S. O’Rahilly
I. N. M. Day
M. S. Sandhu
I. Barroso
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0443-9

Other articles of this Issue 11/2006

Diabetologia 11/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine